Spyre Therapeutics
SYRE
44 hedge funds and large institutions have $12M invested in Spyre Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 8 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.25% less ownership
Funds ownership: 2.77% → 2.53% (-0.25%)
12% less funds holding
Funds holding: 50 → 44 (-6)
38% less capital invested
Capital invested by funds: $19.2M → $12M (-$7.21M)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$265K |
| 2 |
CG
Carlyle Group
Washington,
District of Columbia
|
+$106K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$90.2K |
| 4 |
Jane Street
New York
|
+$18.8K |
| 5 |
Renaissance Technologies
New York
|
+$13.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$472K |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$360K |
| 3 |
Two Sigma Investments
New York
|
-$32.1K |
| 4 |
Morgan Stanley
New York
|
-$29.3K |
| 5 |
Two Sigma Advisers
New York
|
-$27.2K |
SYRE Hedge Fund Activity: Q1 2023 in Review
44 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q1 2023, worth a combined $12M — down 38% from $19.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SYRE and 3 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 9 added.
The largest buyer was Millennium Management, adding an estimated $265K. The largest seller was Pura Vida Investments, exiting entirely with an estimated $472K sold.
- 44 institutional investors held Spyre Therapeutics (SYRE) as of Q1 2023, down from 50 in Q4 2022.
- Funds reported $12M of Spyre Therapeutics stock for Q1 2023, down 38% quarter-over-quarter.
- 3 funds opened new Spyre Therapeutics positions in Q1 2023 and 8 closed out, a net change of -5 holders.
- The largest Spyre Therapeutics buyer in Q1 2023 was Millennium Management, an estimated $265K added.
- The largest Spyre Therapeutics seller in Q1 2023 was Pura Vida Investments, an estimated $472K sold.
Based on aggregated 13F filings for Q1 2023.